These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

489 related articles for article (PubMed ID: 19109437)

  • 1. A conserved protonation-dependent switch controls drug binding in the Abl kinase.
    Shan Y; Seeliger MA; Eastwood MP; Frank F; Xu H; Jensen MØ; Dror RO; Kuriyan J; Shaw DE
    Proc Natl Acad Sci U S A; 2009 Jan; 106(1):139-44. PubMed ID: 19109437
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Src-like inactive conformation in the abl tyrosine kinase domain.
    Levinson NM; Kuchment O; Shen K; Young MA; Koldobskiy M; Karplus M; Cole PA; Kuriyan J
    PLoS Biol; 2006 May; 4(5):e144. PubMed ID: 16640460
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Computational study of the "DFG-flip" conformational transition in c-Abl and c-Src tyrosine kinases.
    Meng Y; Lin YL; Roux B
    J Phys Chem B; 2015 Jan; 119(4):1443-56. PubMed ID: 25548962
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The transition between active and inactive conformations of Abl kinase studied by rock climbing and Milestoning.
    Narayan B; Fathizadeh A; Templeton C; He P; Arasteh S; Elber R; Buchete NV; Levy RM
    Biochim Biophys Acta Gen Subj; 2020 Apr; 1864(4):129508. PubMed ID: 31884066
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The different flexibility of c-Src and c-Abl kinases regulates the accessibility of a druggable inactive conformation.
    Lovera S; Sutto L; Boubeva R; Scapozza L; Dölker N; Gervasio FL
    J Am Chem Soc; 2012 Feb; 134(5):2496-9. PubMed ID: 22280319
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular dynamics simulations show that conformational selection governs the binding preferences of imatinib for several tyrosine kinases.
    Aleksandrov A; Simonson T
    J Biol Chem; 2010 Apr; 285(18):13807-15. PubMed ID: 20200154
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HRD Motif as the Central Hub of the Signaling Network for Activation Loop Autophosphorylation in Abl Kinase.
    La Sala G; Riccardi L; Gaspari R; Cavalli A; Hantschel O; De Vivo M
    J Chem Theory Comput; 2016 Nov; 12(11):5563-5574. PubMed ID: 27682200
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of imatinib and sorafenib binding to p38alpha compared with c-Abl and b-Raf provides structural insights for understanding the selectivity of inhibitors targeting the DFG-out form of protein kinases.
    Namboodiri HV; Bukhtiyarova M; Ramcharan J; Karpusas M; Lee Y; Springman EB
    Biochemistry; 2010 May; 49(17):3611-8. PubMed ID: 20337484
    [TBL] [Abstract][Full Text] [Related]  

  • 9. How Electrostatic Coupling Enables Conformational Plasticity in a Tyrosine Kinase.
    Tsai CC; Yue Z; Shen J
    J Am Chem Soc; 2019 Sep; 141(38):15092-15101. PubMed ID: 31476863
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Computational study of Gleevec and G6G reveals molecular determinants of kinase inhibitor selectivity.
    Lin YL; Meng Y; Huang L; Roux B
    J Am Chem Soc; 2014 Oct; 136(42):14753-62. PubMed ID: 25243930
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Small molecule recognition of c-Src via the Imatinib-binding conformation.
    Dar AC; Lopez MS; Shokat KM
    Chem Biol; 2008 Oct; 15(10):1015-22. PubMed ID: 18940662
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structural basis for the autoinhibition of c-Abl tyrosine kinase.
    Nagar B; Hantschel O; Young MA; Scheffzek K; Veach D; Bornmann W; Clarkson B; Superti-Furga G; Kuriyan J
    Cell; 2003 Mar; 112(6):859-71. PubMed ID: 12654251
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A molecular mechanics model for imatinib and imatinib:kinase binding.
    Aleksandrov A; Simonson T
    J Comput Chem; 2010 May; 31(7):1550-60. PubMed ID: 20020482
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of binding energy activity of imatinib and Abl tyrosine kinase domain based on simple consideration for conformational change: An explanation for variation in imatinib effect in mutated type.
    Wiwanitkit V
    Indian J Cancer; 2009; 46(4):335-6. PubMed ID: 19749465
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chemotherapeutic drug selectivity between wild-type and mutant BRaf kinases in colon cancer.
    Zhang J; Ji T
    J Mol Model; 2017 Jan; 23(1):1. PubMed ID: 27921184
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Allosteric inhibition of c-Met kinase in sub-microsecond molecular dynamics simulations induced by its inhibitor, tivantinib.
    Yan M; Wang H; Wang Q; Zhang Z; Zhang C
    Phys Chem Chem Phys; 2016 Apr; 18(15):10367-74. PubMed ID: 27029952
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Computational analysis and prediction of the binding motif and protein interacting partners of the Abl SH3 domain.
    Hou T; Chen K; McLaughlin WA; Lu B; Wang W
    PLoS Comput Biol; 2006 Jan; 2(1):e1. PubMed ID: 16446784
    [TBL] [Abstract][Full Text] [Related]  

  • 18. c-Src binds to the cancer drug imatinib with an inactive Abl/c-Kit conformation and a distributed thermodynamic penalty.
    Seeliger MA; Nagar B; Frank F; Cao X; Henderson MN; Kuriyan J
    Structure; 2007 Mar; 15(3):299-311. PubMed ID: 17355866
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Studies of N(9)-arenthenyl purines as novel DFG-in and DFG-out dual Src/Abl inhibitors using 3D-QSAR, docking and molecular dynamics simulations.
    Ma S; Zeng G; Fang D; Wang J; Wu W; Xie W; Tan S; Zheng K
    Mol Biosyst; 2015 Feb; 11(2):394-406. PubMed ID: 25406390
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Atomic view of the energy landscape in the allosteric regulation of Abl kinase.
    Saleh T; Rossi P; Kalodimos CG
    Nat Struct Mol Biol; 2017 Nov; 24(11):893-901. PubMed ID: 28945248
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.